Post Profile

Nine out of 10 NHS groups failing on cancer care, ratings show

NHS England data reveals most clinical commissioning groups are performing poorly, with only 14% doing ‘well’ or better Almost nine out of 10 NHS groups are failing cancer patients, with low rates of diagnosis and treatment, new ratings show. Data from NHS England reveals that most clinical commissioning groups (CCGs) across England are performing poorly when it comes to diagnosing patients quickly, ensuring they get prompt treatment and boosting one-year survival rates.
read more


Related Posts

Clinicians rate patients with lung cancer with poorer quality of life

Health : Medical News Today

Advances have been made in the treatment of lung cancer, but the disease continues to be a challenge to treat, primarily because of a high number of people who have late-stage cancer at the time of diagnosis, the likelihood of poor ...

Moffitt Cancer Center Researchers Target Specific Protein Associated with Poor Survival and Treatment Resistance in Brain Cancer Patients

Health : Newswise Medical News

TAMPA, Fla. - Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. N...

Thyroid Cancer Patients Report Poor Quality of Life Despite 'Good' Diagnosis

Health : Newswise Medical News

Thyroid cancer survivors report poor quality of life after treatment compared with others who have more lethal cancers. The findings shed light on a rarely studied outcome for a growing group of patients who will soon account for 10...

Mayo Clinic Minute: Breast cancer, exercise and lymphedema

Health : Mayo Clinic News Blog

No woman wants to hear the words, "You have breast cancer." The diagnosis can be frightening, and thoughts turn to treatment. Some women worry about complications of treatment, one of which is lymphedema, or swelling of the arms aft...

Follow-Up To REDUCE Study Shows Low Rate Of Prostate Cancer Diagnosis

Health : Medical News Today

Analysis of 2 Years of Additional Data on Dutasteride Treatment Reported in The Journal of Urology® The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in...


Copyright © 2016 Regator, LLC